Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients. (TRAP)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03644303 |
|
Recruitment Status : Unknown
Verified November 2019 by Royal Marsden NHS Foundation Trust.
Recruitment status was: Recruiting
First Posted : August 23, 2018
Last Update Posted : November 14, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This multi-center, phase II trial will be conducted in men with castration resistant prostate cancer. The aim of the TRAP trial is to test whether a new precise radiotherapy technique called stereotactic body radiotherapy (SBRT) can slow down the growth of metastatic prostate cancer. If SBRT is effective it will represent a new treatment option in these patients, providing more prolonged control without having to resort to chemotherapy and its potentially unpleasant side effects.
In this trial, the investigators will identify men who, despite being on next generation androgen deprivation treatment (Abiraterone or Enzalutamide) have developed one or two new sites of worsening (growing) disease but the rest of their cancer is still responding to hormonal therapy. If it is the case that SBRT can successfully treat the cancer which is resistant to current treatment then the investigators hope they will be able to better control the spread of cancer in these patients for longer.
The investigators also hope that they will be able to use the tell-tale products (gene markers) that are released into the bloodstream in these patients, or identify characteristics on novel imaging such as magnetic resonance imaging (MRI) to help identify patients in the future who will benefit the most.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Prostate Cancer Metastasis Toxicity Due to Radiotherapy Circulating Tumour DNA | Radiation: SBRT + ADT | Not Applicable |
For many men with metastatic prostate cancer, the cancer develops resistance to successive systemic therapies and eventually all treatment options are exhausted and the patient succumbs to their disease. It is therefore vital to find ways of evading prostate cancer resistance. Stereotactic body radiotherapy (SBRT) has the advantage that it destroys cancerous tissue irrespective of the underlying genetic deficit within the progressing metastasis. If the resistant clones are localized to 1-2 metastases and can be destroyed or ablated, the patient can continue to receive the benefit of their systemic (androgen deprivation) treatment (Abiraterone or Enzalutamide) which may continue to control the remainder of their disease for many months, possibly even years.
SBRT is a recognised technique for the elimination of isolated metastases in other tumour sites achieving local control of metastasis in 80-90% of cases. This is achieved with very few side effects. In the TRAP trial, the investigators wish to establish whether it is beneficial to target 1 or 2 metastatic sites with SBRT or whether patients will develop polymetastatic progression. Patients enrolled on the trial will receive 30 Gy in 5 fractions on alternate days over 10 days. They will continue their androgen deprivation treatment throughout and following SBRT. Side effects will be closely monitored throughout and patients will be seen at the end of radiotherapy and then 4 weeks after treatment. Thereafter patients will undergo trial follow up three monthly which will includes Prostate Specific Antigen (PSA) monitoring.
In addition to the above procedures, the investigators will use a combination of whole body (WB) diffusion weighted (DW) magnetic resonance imaging (WB DW MRI) and circulating tumour (ct) deoxyribonucleic acid (DNA), 'ct DNA' biomarker analysis with the aim of identifying those patients which benefit most from the combination of SBRT and androgen deprivation treatment. WB DW MRI is a novel MRI technique which shows improved sensitivity compared to standard MRI. The marker ctDNA enables the investigators to explore genomic characterisation and variation of metastases and compare findings with previously explored genome mutations in prostate cancer patients.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 84 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Intervention Model Description: | Single arm, prospective interventional cohort study |
| Masking: | None (Open Label) |
| Masking Description: | Interpretation of the two paired WB DW MRI scans (baseline and 6 months) will be conducted by one assessor will be blinded to the identity of the baseline scan to ensure minimisation of any potential bias. |
| Primary Purpose: | Treatment |
| Official Title: | TRAP - Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients. |
| Actual Study Start Date : | August 13, 2018 |
| Estimated Primary Completion Date : | October 1, 2020 |
| Estimated Study Completion Date : | October 1, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: SBRT + ADT
Enzalutamide OR Abiraterone at licensed doses in combination with stereotactic radiotherapy: 30 Gray in 5 fractions
|
Radiation: SBRT + ADT
Short course SBRT to 1 or 2 oligo-progressing metastases in addition to continued abiraterone or enzalutamide
Other Name: Enzalutamide or Abiraterone plus stereotactic radiotherapy |
- Median Progression-Free Survival (PFS) [ Time Frame: Outcome to be assessed at 6 months from end of SBRT ]Median progression free survival following SBRT to oligo-progressing metastatic sites assessed using the RECIST (v 1.1) criteria on imaging such as computed Tomography (CT),bone scan, magnetic Resonance Imaging (MRI) or Positron Emission Tomography (PET) scan
- Local control rate following SBRT [ Time Frame: Outcome to be assessed at 6 months and 1 year from end of SBRT ]Overall control defined as stable disease or partial response of irradiated metastases assessed using the RECIST (v 1.1) criteria on imaging such as computed Tomography (CT), magnetic Resonance Imaging (MRI) or Positron Emission Tomography (PET) scan or control on bone scan
- Incidence and severity of treatment induced symptoms [ Time Frame: From the start of SBRT up to 24 months following delivery of SBRT ]Incidence of acute and late side-effects resulting from SBRT assessed using the Common Terminology Criteria for Adverse Events (CTCAE) and the Radiotherapy and Oncology Group Terminology Criteria for Adverse Events (CTCAE) and the RTOG (Radiotherapy Oncology Group) scoring criteria
- Health Related Quality of Life [ Time Frame: Change from start of radiotherapy to each time-point including 3 and 6 months after end of SBRT ]Patient Reported Quality of Life assessed using the Euroqual (EQ) EQ-5D-5L questionnaire
- Time to administration of next line of therapy [ Time Frame: From the end of SBRT up to 24 months following delivery of SBRT ]Survival and median survival prior to alternative therapy administration
- Association between selected WB DW MRI characteristics at baseline and prognosis after SBRT [ Time Frame: Outcome to be assessed at 6 months and 1 year from end of SBRT ]Correlation or regression analysis of characteristics (e.g. number of metastases)
- Exploration of novel bio-markers to assess response to SBRT treatment [ Time Frame: Assessment of Progression Free Survival at 6 months and 1 year ]Levels of circulating tumor Deoxyribonucleic Acid (ctDNA)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Male |
| Gender Based Eligibility: | Yes |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Be willing and able to provide written informed consent for the trial and be ≥18 years of age on day of signing informed consent.
- Have metastatic Castration Resistant Prostate Cancer (CRPC) based on biochemical or pathological diagnosis and be on Enzalutamide or Abiraterone.
- Have had a minimum of 6 months on Enzalutamide or Abiraterone with evidence of response (PSA, radiological or symptomatic)
- Have 1 - 2 metastatic lesions progressing on imaging (CT, bone scan, MRI or other local imaging) or a clinical or imaging diagnosis of progression of a non-irradiated primary site with the remainder of their metastases currently controlled by Enzalutamide or Abiraterone.
- Have had no previous radical radiation to the index area (defined as unable to deliver SBRT doses in this protocol without taking normal tissues beyond tolerance).
- Have a Performance Status (PS) assessed using the Eastern Co-operative Oncology Group (ECOG) criteria of 0 - 1.
- Have an oligoprogressing site, including those that have developed on treatment, in bone, lymph node, prostate or lung but not in liver, brain, adrenal or other sites.
- Patients may be symptomatic in the oligoprogressing area. However, there is no urgent need to start radiotherapy.
Exclusion Criteria:
- A clinical need exists to switch therapy immediately (e.g. suspicion of rapid clinical progression, urgent need for palliative radiotherapy).
- Evidence of previous invasive cancer in the last 5 years, with the exception of non-melanoma skin cancer (non-invasive malignancies such as non-muscle invasive bladder cancer are not excluded).
- There is a contra-indication to radiotherapy (e.g. inflammatory bowel disease).
- There is a contra-indication to MRI where required for radiotherapy (e.g. cardiac pacemaker, internal defibrillator, shrapnel injury or claustrophobia).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03644303
| Contact: Linda Wedlake, PhD | +44 208 915 6767 | linda.wedlake@rmh.nhs.uk | |
| Contact: Victoria Pittordou, BSc | + 44 208 915 6766 | victorai.pittordou@rmh.nhs.uk |
| United Kingdom | |
| The Christie NHS Foundation Trust | Not yet recruiting |
| Manchester, Manchester Greater, United Kingdom, M20 4BX | |
| Contact: Ananya Choudhury, PhD | |
| Belfast Health & Social care Trust | Not yet recruiting |
| Belfast, Northern Ireland, United Kingdom, BT8 8BH | |
| Contact: Suneil Jain | |
| The Royal Marsden NHS Foundation Trust | Recruiting |
| Sutton, Surrey, United Kingdom, SM5 3EZ | |
| Contact: L J Wedlake, PhD 2089156767 linda.wedlake@rmh.nhs.uk | |
| Contact: V J Pittordou, BSc 02089156766 victoria.pittordou@rmh.nhs.uk | |
| Principal Investigator: Alison Tree, FRCR | |
| Sub-Investigator: Gerhardt Attard, PhD | |
| Sub-Investigator: NIna Tunariu, PhD | |
| Sub-Investigator: Nicholas VanAs, MBBS | |
| The Newcastle Upon Tyne Hospitals NHS Foundation Trust | Not yet recruiting |
| Newcastle Upon Tyne, Tyne And Wear, United Kingdom, NE7 7DN | |
| Contact: John Frew, MBBS | |
| Velindre Cancer Centre | Not yet recruiting |
| Cardiff, Wales, United Kingdom, CF14 2TL | |
| Contact: John Staffurth, MBBS | |
| University Hospitals Birmingham NHS Foundation Trust | Not yet recruiting |
| Birmingham, West Midlands, United Kingdom, B15 2TH | |
| Contact: Daniel Ford, MBBS | |
| Leeds Teaching Hospitals NHS Trust | Not yet recruiting |
| Leeds, West Yorkshire, United Kingdom, LS9 7TF | |
| Contact: Ann Henry, PhD | |
| Principal Investigator: | Alison Tree, FRCR | Royal Marsden NHS Foundation Trust |
| Responsible Party: | Royal Marsden NHS Foundation Trust |
| ClinicalTrials.gov Identifier: | NCT03644303 |
| Other Study ID Numbers: |
CCR 4781 |
| First Posted: | August 23, 2018 Key Record Dates |
| Last Update Posted: | November 14, 2019 |
| Last Verified: | November 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Human tissue (blood) in surplus will be made available for other ethically approved research provided patients have given their informed consent |
| Time Frame: | Not anticipated to be before 6 months have elapsed following recruitment of the last patient. |
| Access Criteria: | On provision of written request |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms |
Genital Diseases, Male Genital Diseases Urogenital Diseases Prostatic Diseases Male Urogenital Diseases |